
Biomarker identifies high-risk COVID-19 patients
The findings of virologists headed by Elisabeth Puchhammer-Stöckl from the Medical University Vienna may pave the way to early identification of...

Servier and MiNA Therapeutics sign €220m deal
Under the agreement, MiNA Therapeutics will use its small activating RNA platform (saRNA) to identify candicate saRNAs that can restore normal cell...

LSP reports first closing of dementia fund
The LSP Dementia Fund is the first fund globally dedicated to fight neurodegenerative diseases with help of drug and medtech solutions. The fund will...

C4X Discovery and Sanofi ink €414m IL-17A blocker R&D contract
The company's subsidiary C4X Discovery Ltd got €7m upfront with potential to gain €414m in total for the global commercialisation rights for its...

Step Pharma SAS raises €35m in Series B
The financing round of the French drug development company was co-led by new investors Hadean Ventures and Sunstone Life Science Ventures with...

Novel strategy targets chronic liver diseases
The approach published in Nature Cancer leads to a cell-toxic accumulation of saturated fatty acids that drives tumour cells into apoptosis. HCC...

Cellectis and Cytovia in US$760m licence deal
Cytovia Therapeutics, Inc. and French Cellectis SAS have struck a licence deal to combine their different expertises in allogenic cancer cell...